Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2011 2
2012 1
2014 1
2015 1
2016 2
2017 2
2020 1
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE. Crump M, et al. Among authors: djurfeldt ms. J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29. J Clin Oncol. 2014. PMID: 25267740 Free article. Clinical Trial.
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.
Gupta A, Hay AE, Crump M, Djurfeldt MS, Zhu L, Cheung MC, Shepherd LE, Chen BE, Booth CM. Gupta A, et al. Among authors: djurfeldt ms. Oncologist. 2023 Sep 7;28(9):799-803. doi: 10.1093/oncolo/oyad128. Oncologist. 2023. PMID: 37226534 Free PMC article. Clinical Trial.
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.
Prica A, Hay AE, Crump M, Mittmann N, Shepherd LE, Meyer RM, Imrie KI, Risebrough N, Djurfeldt M, Chen BE, Cheung MC. Prica A, et al. Among authors: djurfeldt m. Curr Oncol. 2021 Mar 17;28(2):1256-1261. doi: 10.3390/curroncol28020119. Curr Oncol. 2021. PMID: 33802634 Free PMC article.
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. Meyer RM, et al. Among authors: djurfeldt ms. N Engl J Med. 2012 Feb 2;366(5):399-408. doi: 10.1056/NEJMoa1111961. Epub 2011 Dec 11. N Engl J Med. 2012. PMID: 22149921 Free PMC article. Clinical Trial.
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T. Han M, et al. Among authors: djurfeldt m. Blood. 2016 Aug 4;128(5):732-5. doi: 10.1182/blood-2016-06-716902. Epub 2016 Jun 23. Blood. 2016. PMID: 27338095 Free article. No abstract available.
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.
Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, van den Neste E, Shepherd LE, Schmitz N, Baetz T, Keating A, Robinson S, Seftel M, Stelitano C, Djurfeldt MS, Meyer R, Chen BE, Crump M. Assouline S, et al. Among authors: djurfeldt ms. Blood Adv. 2020 May 12;4(9):2011-2017. doi: 10.1182/bloodadvances.2020001646. Blood Adv. 2020. PMID: 32396614 Free PMC article.
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D, Stakiw J, Laferriere N, Luminari S, Shepherd LE, Djurfeldt M, Zhu L, Chen BE, Hay AE. Skamene T, et al. Among authors: djurfeldt m. Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15. Leuk Lymphoma. 2017. PMID: 28504033 Clinical Trial.
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>
Baetz T, Chen BE, Couban S, Tom Kouroukis C, Buckstein R, Kuruvilla J, Howson-Jan K, Szwajcer D, Federico M, Meyer RM, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Baetz T, et al. Among authors: djurfeldt ms. Leuk Lymphoma. 2017 Jan;58(1):64-69. doi: 10.1080/10428194.2016.1187274. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27266754
15 results